Rigel Pharma (RIGL) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $47.28 +0.13%
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -34.9%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q2 EPS of ($0.06), $0.04 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $36.84 million versus the consensus estimate of $33.7 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft plans data center push to triple its computing power - Bloomberg
- RH (RH) Tops Q2 EPS by $2.31
- UBS Upgrades SD Guthrie (SDG:MK) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
